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Effects of route of administration of a commercially available Mannheimia
(pasteurella) haemolytica vaccine on titer levels
Abstract
One hundred thirteen Hereford x Angus heifer calves (average weight = 515 lb) were allotted to one of
three treatments: 1) control, no vaccine; 2) a 2-cc subcutaneous injection of One-Shot® (Pfizer Animal
Health), a Mannheimia (pasteurella) haemolytica vaccine, three weeks before weaning; or 3) a ½-cc
intradermal injection of One-Shot, three weeks before weaning. All heifers were weighed and blood
samples harvested at time of injection, three weeks later at weaning, and then 28 days later. After
weaning, heifers were confined to a common pen and fed free-choice brome hay and approximately 5 lb/
head daily of a concentrate. Blood samples from 30 heifers were shipped to a laboratory for titer analysis.
No differences were found in animal performance and sickness during the preconditioning period. Heifers
injected by the subcutaneous route had greater increases in whole-cell and leukotoxin-neutralizing
antibody titer levels than the intradermal or control treatments. These data suggest that beef producers
should follow label recommendations for dosage and route of administration to maximize vaccine
efficacy.
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EFFECTS OF ROUTE OF ADMINISTRATION OF A COMMERCIALLY
AVAILABLE MANNHEIMIA (PASTEURELLA) HAEMOLYTICA
VACCINE ON TITER LEVELS
T. T. Marston, L. C. Hollis, D. A. Llewellyn, and G. L. Stokka1

Summary

Introduction

One hundred thirteen Hereford x Angus
heifer calves (average weight = 515 lb) were
allotted to one of three treatments: 1) control,
no vaccine; 2) a 2-cc subcutaneous injection
of One-Shot® (Pfizer Animal Health), a
Mannheimia (pasteurella) haemolytica vaccine, three weeks before weaning; or 3) a ½-cc
intradermal injection of One-Shot, three
weeks before weaning. All heifers were
weighed and blood samples harvested at time
of injection, three weeks later at weaning, and
then 28 days later. After weaning, heifers
were confined to a common pen and fed freechoice brome hay and approximately 5
lb/head daily of a concentrate. Blood samples
from 30 heifers were shipped to a laboratory
for titer analysis. No differences were found
in animal performance and sickness during the
preconditioning period. Heifers injected by
the subcutaneous route had greater increases
in whole-cell and leukotoxin-neutralizing antibody titer levels than the intradermal or control treatments. These data suggest that beef
producers should follow label recommendations for dosage and route of administration to
maximize vaccine efficacy.

Mannheimia haemolytica is the major bacterium responsible for severe disease (bovine
respiratory disease) and economic losses in
cattle. Research has indicated that weanling
calves vaccinated subcutaneously for M.
haemolytica with One-Shot® (Pfizer Animal
Health) responded with a significant increase
in whole-cell and leukotoxin-neutralizing antibody titers. Increasing titers would indicate
that the animal’s immune system reacted to
the vaccine and is better prepared to defend
the body against disease challenges. This
study was conducted to determine if use of an
intradermal route of administration with a
smaller dosage would elevate antibody titers
and have the potential to reduce morbidity and
increase performance in cattle.

1

Experimental Procedures
One hundred thirteen Hereford x Angus,
spring-born heifers were randomly assigned to
treatments three weeks before weaning (September 24, 2002). Heifers were weighed, and
blood samples were harvested before vaccination and were properly stored. Heifers were
then processed with FORTRESS 7® (Pfizer

Pfizer Animal Health, Cooperstown, North Dakota.
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Animal Health) and CATTLEMASTER 4®
(Pfizer Animal Health). According to treatment assignment, heifers received one of three
injection treatments of a M. haemolytica vaccine (One-Shot®, Pfizer Animal Health): 1)
control, no vaccine administered; 2) a 2-cc
subcutaneous injection of the M. haemolytica
vaccine; or 3) a ½-cc intradermal injection of
the M. haemolytica vaccine. Twenty-one days
later (October 14), heifers were again weighed
and blood samples taken and properly stored.
Samples from both sampling days were forwarded to Oklahoma State University for
whole-cell and leukotoxin-neutralizing antibody analysis. Two blood samples were not
analyzed. All injections were given in the
calves’ neck region, following standard KSU/
KVMA/KLA Beef Quality Assurance guidelines.

gains and morbidity were similar between
treatments. No differences in basal titer levels
were noted between treatments groups (Table
2). Changes in whole-cell titer in response to
vaccination were not different among treatments (P>0.55). However, the leukotoxinneutralizing antibody tests indicated that the
subcutaneous treatment resulted in a greater
increase in antibody concentration than either
the control (P=0.004) or intradermal (P=0.21)
treatments.
These heifers were neither transported nor
commingled with externally sourced cattle
during this trial. Health records reflected this
management program, in as much as no heifers were treated for bovine respiratory disease
or died during the preconditioning period.
One-Shot vaccine was effective in increasing the leukotoxin-neutralizing antibody titer
levels in weaning-age calves, whereas wholecell titers were less responsive. The recommended route of administration and dosage
seems to give best results.

Results and Discussion
The initial weight of heifers treated intradermally was less than heifers in other
treatments, but initial weight had no effect on
gain or blood-work results (Table 1). Weight
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Table 1. Effects of Volume and Route of Administration of a Mannheimia haemolytica
Vaccine (One-Shot®, Pfizer Animal Health) on Animal Performance
Item:
Initial weight, lb

Control/
No Vaccine
a

512

2 cc
Subcutaneous
521

a

½ cc
Intradermal
b

500

SEM
6.2

Average daily gain, lb/day

ab

September 24 to October 15

1.6

1.7

1.7

0.12

October 15 to November 12

1.3

1.4

1.2

0.10

September 24 to November 12

1.5

1.5

1.5

0.04

Means with different superscripts within row differ (P<0.05).

Table 2. Effects of Volume and Route of Administration of a Mannheimia haemolytica
Vaccine (One-Shot®, Pfizer Animal Health) on Serological Test Results
Control/
No Vaccine

2 cc
Subcutaneous

½ cc
Intradermal

SEM

Whole cell

0.28

0.32

0.43

0.11

LktNA*

0.16

0.18

0.15

0.050

0.37

0.64

0.54

0.12

Item:
Titer level, September 24

Titer level, October 14
Whole cell
LktNA*

a

b

0.22

a

0.48

0.33

0.063

0.30

0.21

0.12

Change in titer level, September 24 to October 14
Whole cell
LktNA*

0.04
a

b

0.05

0.33

*Leukotoxin-neutralizing antibody.
ab

Means with different superscripts within row differ (P<0.10).
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0.17

a

0.069

